Active Mesothelioma Clinical Trials

Below is a partial listing of mesothelioma clinical trials that are being sponsored by medical facilities throughout the United States. Click on the Clinical Trial Identifier to open and download more details about each trial.

Clinical Trial Identifier: NCT00715611
Sponsor: Memorial Sloan Kettering Cancer Center
Purpose of this Clinical Trial: There is a new radiation technique using Intensity Modulated
Radiation Therapy (IMRT) that has been shown to reduce many of the side effects of standard radiation therapy. This type of radiation therapy specifically targets the lining of the lung, where you have your cancer, and reduces the risk of damaging the lung itself. The purpose of this study is to test the safety and implementation of standard pleurectomy/decortication (removal of the surface lining of the lung) performed at other centers. Patients will undergo pleurectomy/decortication chemotherapy and hemithoracic pleural IMRT to the pleura in patients with malignant pleural mesothelioma.

Clinical Trial Identifier: NCT01503177
Sponsor: Mayo Clinic
Purpose of this Clinical Trial: This phase I clinical trial investigates the side effects and the best dose of local (intrapleural measles virus therapy in treating patients with malignant pleural mesothelioma (MPM). The investigators anticipate that the intrapleural of the vaccine strain measles virus will enable the virus to specifically infect and kill cancer cells and spare, without damaging normal cells. Furthermore, the investigators expect the measles virus to trigger an anti-tumor immune response which will result in additional destruction of the tumor by immune cells

Clinical Trial Identifier: NCT01583686
Sponsor: National Cancer Institute (NCI)
Purpose of this Clinical Trial: The NCI Surgery Branch has developed an experimental therapy for treating patients with metastatic cancer that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying these specific cells with a type of virus (retrovirus) to attack only the tumor cells, and then giving the cells back to the patient. This type of therapy is called gene transfer. In this protocol, we are modifying the patient s white blood cells with a retrovirus that has the gene for anti-mesothelin incorporated in the retrovirus. Objective: The purpose of this study is to determine a safe number of these cells to infuse and to see if these tumor fighting cells (anti-mesothelin cells) cause metastatic cancer tumors to shrink.

Clinical Trial Identifier: NCT01624090
Sponsor: National Cancer Institute (NCI)
Purpose of this Clinical Trial: Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment. Research suggests that it may be useful against some cancers of the chest, such as lung and esophageal cancer or mesothelioma. Researchers want to see if mithramycin can be used to treat these types of cancer. Objectives: – To see if mithramycin is safe and effective against different chest cancers.

Clinical Trial Identifier: NCT01655225
Sponsor: Eli Lilly and Company
Purpose of this Clinical Trial: The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have. In Part A of this study, participants with advanced/metastatic cancer (including lymphoma) will receive increasing doses of LY3023414. In Part B, LY3023414 will be explored in different types of cancer, including breast and lung cancer, lymphoma and mesothelioma.

Clinical Trial Identifier: NCT01766739
Sponsor: Memorial Sloan Kettering Cancer Center
Purpose of this Clinical Trial: The purpose of this study is to test the safety of the GL-ONC1 vaccinia virus at different dose levels. The investigators want to find out what effects, good and/or bad, it has on the patient and the malignant pleural effusion. A malignant pleural effusion is a build up of fluid in the chest cavity cause by the cancer.

Clinical Trial Identifier:  NCT01907100
Sponsor: Boehringer Ingelheim
Purpose of this Clinical Trial: This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.

Clinical Trial Identifier:  NCT02071862
Sponsor: Calithera Biosciences, Inc.
Purpose of this Clinical Trial: Many tumor cells, in contrast to normal cells, have been shown to require the amino acid  glutamine to produce energy for growth and survival. To exploit the dependence of tumors on  glutamine, CB-839, a potent and selective inhibitor of the first enzyme in glutamine  utilization, glutaminase, will be tested in this Phase 1 study in patients with solid  tumors.   This study is an open-label Phase 1 evaluation of CB-839 in patients with advanced solid  tumors.

Clinical Trial Identifier:  NCT02151448
Sponsor:
 Pawel Kalinski
Purpose of this Clinical Trial: This trial is to determine the safest dose of a triple combination (chemokine modulatory  regimen or CKM) of celecoxib, interferon alfa (IFN), and rintatolimod that can be given with  a DC vaccine as treatment of peritoneal surface malignancies after standard of care surgery.

Clinical Trial Identifier:  NCT02153229
Sponsor:
 Abramson Cancer Center of the University of Pennsylvania
Purpose of this Clinical Trial: A randomized Phase II trial to test whether the addition of intraoperative  Photofrin-mediated photodynamic therapy to radical pleurectomy and post-operative  chemo.improves OS in the treatment of patients with epithelioid MPM.

Clinical Trial Identifier:  NCT02293005
Sponsor:
 M.D. Anderson Cancer Center
Purpose of this Clinical Trial: The primary objective of this study is to:   To assess 4-month disease control rate (DCR) in pre-treated patients with unresectable  malignant pleural mesothelioma (MPM) treated with alisertib   The secondary objectives of this study are to:   To assess the response rate (confirmed and unconfirmed complete + partial responses) To  assess the progression-free survival. To assess overall survival. To evaluate the side  effects and toxicities associated with this treatment regimen. To collect archival tissue, blood, pleural effusion fluid and plasma for correlative  studies.

Clinical Trial Identifier: NCT02349412
Sponsor:
 Alliance for Clinical Trials in Oncology
Purpose of this Clinical Trial: The study intervention consists of the early integration of palliative care services into standard oncology care in an outpatient setting for patients with advanced lung and non-colorectal gastrointestinal malignancies who are not being treated with curative intent. The palliative care services provided to patients randomized to the intervention will be provided by board-certified physicians and/or advanced practice nurses and will focus on the following areas: (1) developing and maintaining the therapeutic relationship with the patients and family caregivers; (2) assessing and treating patient symptoms; (3) providing support and reinforcement of coping with advanced cancer in patients and family caregivers; (4) assessing and enhancing prognostic awareness and illness understanding in patients and family caregivers; (5) assisting with treatment decision-making; and (6) end-of-life care planning.

Clinical Trial Identifier: NCT02357147 
Sponsor:
 Morphotek
Purpose of this Clinical Trial: This is a multicenter, double-blind, randomized, parallel-group study, using a placebo control or amatuximab 5 mg/kg, administered weekly, designed to evaluate the safety and efficacy of amatuximab in combination with pemetrexed and cisplatin in subjects with unresectable Malignant Pleural Mesothelioma who have not received prior systemic therapy.

Clinical Trial Identifier: NCT02381314 
Sponsor:
 MacroGenics
Purpose of this Clinical Trial: The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC) and other B7H3 expressing cancers. The study will also evaluate what is the best dose of enoblituzumab to use when given with ipilimumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of enoblituzumab in combination with ipilimumab.

Clinical Trial Identifier: NCT02399371 
Sponsor:
 University of Chicago
Purpose of this Clinical Trial: This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum). Monoclonal antibodies, such as pembrolizumab, work by blocking a protein called programmed cell death 1 (PD-1) which may stimulate an immune response and kill tumor cells.

Clinical Trial Identifier:  NCT02408016
Sponsor:
  Fred Hutchinson Cancer Research Center
Purpose of this Clinical Trial: This phase I/II trial studies the side effects and best dose of genetically modified T cells in treating patients with stage III-IV non-small cell lung cancer (NSCLC) or mesothelioma. Many types of cancer cells, including NSCLC and mesothelioma, but not most normal cells, have a protein called Wilms tumor (WT)1 on their surfaces. This study takes a type of immune cell from patients, called T cells, and modifies their genes in the laboratory so that they are programmed to find cells with WT1 and kill them. The T cells are then given back to the patient. Cyclophosphamide and aldesleukin may also stimulate the immune system to attack cancer cells. Giving cyclophosphamide and aldesleukin with laboratory-treated T cells may help the body build an immune response to kill tumor cells.

Clinical Trial Identifier:  NCT02414269
Sponsor:
  Memorial Sloan Kettering Cancer Center
Purpose of this Clinical Trial: The purpose of this Phase I study is to test the safety of different doses of specially prepared immune cells (called “T cells”) collected from blood. The Investigators want to find a safe dose of these modified T cells for patients who have malignant pleural disease. They want to find out what effects these T cells have on the patient and the
cancer (MPD).

Clinical Trial Identifier:  NCT02464904
Sponsor:
  Mayo Clinic
Purpose of this Clinical Trial:  Can neoadjuvant intrapleural cryotherapy be safely performed in patients with malignant pleural mesothelioma and will it trigger substantial systemic and local pro-inflammatory changes, resulting in the induction of anti-tumor immunity?

Clinical Trial Identifier:  NCT02475213
Sponsor:
  MacroGenics
Purpose of this Clinical Trial: The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Keytruda
(pembrolizumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC), and other B7-H3 expressing cancers. The study will also evaluate what is the highest dose of enoblituzumab that can be given safely when given with pembrolizumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of MGA271 in combination with pembrolizumab.

Clinical Trial Identifier:  NCT02535312
Sponsor:
  National Cancer Institute (NCI)
Purpose of this Clinical Trial: This phase I/II trial studies the side effects and the best dose of methoxyamine when given together with cisplatin and pemetrexed disodium and to see how well it works in treating patients with solid tumors or mesothelioma that have spread to other places in the body and usually cannot be cured or controlled with standard treatment
(advanced), or mesothelioma that does not respond to pemetrexed disodium and cisplatin or carboplatin (refractory).  Methoxyamine may shrink the tumor and may also help cisplatin and pemetrexed disodium work better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as cisplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving methoxyamine together with cisplatin and pemetrexed disodium may be a better treatment for solid tumors or mesothelioma.

Clinical Trial Identifier:  NCT02568449
Sponsor:
 Barbara Ann Karmanos Cancer Institute
Purpose of this Clinical Trial: This phase II trial studies how well nintedanib works in treating patients with malignant pleural mesothelioma that has come back. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.